Can Surgery Partners (SGRY) Stock Reach $18?

Key Takeaways

• The central $18 target is the arithmetic mean of nine current, verified analyst price targets on Surgery Partners, Inc. (SGRY), rounded from roughly $18.3.
• With the stock recently near $14.24, reaching $18 implies a gain of about 26% — a substantial move, not a trivial one.
• The individual target range is wide, from $14 to $24, reflecting a genuine split between cautious and bullish views.
• The strongest supports are the long-term shift toward outpatient surgery, portfolio divestitures, and deleveraging.
• The biggest risks are persistent margin pressure, elevated leverage with floating-rate debt, and a slower acquisition pipeline.

Analyst Price Targets and Consensus View

Surgery Partners, Inc. is a healthcare services company that owns and operates ambulatory surgical centers, short-stay surgical facilities, and ancillary services across the United States. Nine current, individually attributed analyst price targets were reviewed, ranging from a low of $14 (Barclays, Hold) to a high of $24 (Benchmark, Buy). The arithmetic mean of these targets is approximately $18.3, which rounds to a clean central target of $18.

Views are clearly divided. Bullish firms cluster in the high-teens to low-$20s — RBC Capital and TD Cowen at $19, Mizuho at $19, Bank of America at $20, Cantor Fitzgerald at $18, and Jefferies at $17 — citing the durable secular shift of procedures into lower-cost ambulatory settings, expected proceeds from facility divestitures, and a return to profitability. More cautious voices sit at $14–$15 (Barclays and JPMorgan), emphasizing margin pressure from payer mix, anesthesia costs, and softer procedure volumes. There is no Sell consensus; the mix is best described as a "Moderate Buy" leaning.

Recent actions include JPMorgan raising its target to $15 from $14 (Neutral), Bank of America lifting to $20 from $18 (Buy), TD Cowen raising to $19 from $17, and RBC trimming to $19 from $20. The overall average analyst price target has drifted down over the past year from the low-$30s, reflecting repeated revisions after guidance cuts.

Current Market Position and Path Toward the Target

The stock has recently traded around $14.24, near its 50-day moving average of roughly $14.25 and within a 52-week range of approximately $11.41 to $23.44. Reaching $18 would require a gain of about 26% from that level, which is a substantial move relative to the shares' recent trading range.

Fundamentally, the company continues to grow revenue — its latest quarter showed revenue of roughly $848.9 million, up about 2.7% year over year and ahead of estimates — while still posting a net loss as higher operating costs weigh on margins. Management has affirmed same-facility revenue growth of about 5%. The investment case rests on execution: converting volume growth into margin expansion, completing planned divestitures to pay down debt, and restoring GAAP profitability. The stock's high beta (near 1.9) means the path could be volatile in either direction.

What Could Support a Move Toward the Target

• Outpatient shift: Payers and employers continue steering procedures to ambulatory surgical centers, a structural tailwind for SGRY's core business.
• Portfolio optimization: The planned sale of facilities, including two community hospitals in Idaho Falls with expected proceeds near $795 million, could improve cash conversion and fund deleveraging.
• Deleveraging: Meaningful debt reduction would ease interest expense, which currently pressures earnings given the company's floating-rate exposure.
• Return to profitability: Analysts broadly expect a swing to positive earnings per share (EPS) in 2026, an inflection that could support the valuation.

What Could Prevent the Target From Being Reached

• Margin pressure: Payer mix, anesthesia costs, and labor expenses have repeatedly forced guidance lower.
• Leverage and rates: With debt-to-equity above 100% and floating-rate borrowings, elevated interest rates directly raise costs.
• Slower M&A: A reduced acquisition pipeline removes a historical driver of growth and cash flow.
• Sentiment and valuation: The stock has already seen its consensus target fall sharply over the past year; further revisions would compound that pressure.

Technical Levels and Market Structure

The stock recently broke below its 50-day moving average (about $14.25) and sits near its 200-day average (about $14.37), a cluster that now acts as nearby resistance. Below, the recent intraday low near $13.68 and the 52-week low near $11.41 are the key support levels. Above, the $18 area — where several analyst targets converge — represents the first major psychological and resistance level on the way toward the high-teens and $20 zone.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary. The next earnings report, scheduled around early November 2026, is the most important near-term event, followed by management's full-year guidance and any updates on the divestiture proceeds and debt reduction. Investors should also watch analyst revisions, Federal Reserve rate decisions (which affect floating-rate borrowing costs), and the pace of same-facility volume and margin recovery.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors tracking SGRY, pairing fundamental research with AI-generated technical signals can offer an additional lens on momentum and timing.

Final Assessment

The $18 central target is an arithmetic mean of nine verified analyst price targets, rounded from about $18.3, and sits well above the stock's recent level near $14.24 — implying a required gain of roughly 26%. The target is supported by the long-term outpatient surgery trend, asset divestitures, and deleveraging, but is challenged by persistent margin pressure, high leverage, and a wide $14-to-$24 analyst range that reflects real disagreement. Whether the stock approaches $18 will likely depend on margin execution and the company's progress reducing debt rather than on top-line growth alone. Investors should monitor upcoming earnings, guidance, and analyst revisions rather than treat the average analyst price target as a guarantee.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations